References
- McLaughlin JL. Peyote: an introduction. Lloydia 1973; 36:1–8.
- Erowid Peyote (Lophophora williamsii) Vault. Available at: http://www.erowid.org/plants/peyote/peyote.shtml. Accessed 27 October 2009.
- Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Giffin SL. 2007 Annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 25th annual report. Clin Toxicol (Phila) 2008; 46:927–1057.
- Lumholtz C. Unknown Mexico. London: MacMillan and Co., Limited; 1903:356–379.
- Schultes RE. The appeal of peyote (Lophophora williamsii) as a medicine. Am Anthropol 1938; 40:698–715.
- US Code: Title 42, 1996a. Traditional Indian religious use of peyote. Available at: http://www.law.cornell.edu/uscode/search/display.html?terms= 1996a&url=/uscode/html/uscode42/usc_sec_42_00001996—a000-.html. Accessed 27 October 2009.
- Bergman RL. Navajo peyote use: its apparent safety. Am J Psychiatry 1971; 128:695–699.
- Nolte KB, Zumwalt RE. Fatal peyote ingestion associated with Mallory-Weiss lacerations. West J Med 1999; 170:328.
- Hashimoto H, Clyde VJ, Parko KL. Botulism from peyote. N Engl J Med 1998; 339:203–204.
- Shulgin AT. Mescaline: the chemistry and pharmacology of its analogs. Lloydia 1973; 36:46–58.
- Aboul-Enein HY. Mescaline: a pharmacological profile. Am J Pharm Sci Support Public Health 1973; 145:125–128.
- The NHSDA Report: Racial and Ethnic Differences in Youth Hallucinogen Use. Available at: http://www.oas.samhsa.gov/2k3/youth Hallucinogens/youthHallucinogens.pdf. Accessed 18 December 2009.
- Hermle L, Fünfgeld M, Oepen G, Botsch H, Borchardt D, Gouzoulis E, Fehrenbach RA, Spitzer M. Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. Biol Psychiatry 1992; 32:976–991.